MedTrace Logo

Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients

NCT01156012 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 404

Last updated 2015-01-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of T2345 versus active comparator.

Conditions

Interventions

DRUG

T2345

One drop of T2345

DRUG

Prostaglandin

One drop

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01156012 on ClinicalTrials.gov